Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.15B
- EPS (TTM)
- -$4.29
- Dividend yield
- None
- 52-week range
- 22.33 – 45.14
- Day range
- 26.64 – 28.43
- Volume / Avg
- 1.72M / 1.33M
- Beta
- —
- Shares outstanding
- 78.55M
52-week range
CLDX stock today
On Nov 20, CLDX ended the session at $27.42, shedding $0.54 (1.93%), versus the S&P 500's 3.70% decline. Shares are 39.3% below their 52-week high of $45.14, set on Aug 12, 2026 and 22.8% above the 52-week low of $22.33, in the middle of the past year's range. CLDX is up 1.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 5.8%.
Celldex Therapeutics has posted a net loss over the last twelve months (EPS of -$4.29), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Celldex Therapeutics
Company profileCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Anthony S. Marucci M.B.A.
- Headquarters
- Hampton, NJ
- Employees
- 198
- Website
- celldex.com
Financial highlights
Full financialsIn fiscal 2025, Celldex Therapeutics generated $1.5 million in revenue, down 78.0% from fiscal 2024, its first annual decline since 2022. Celldex Therapeutics reported a net loss of $258.8 million, compared with a loss of $157.9 million a year earlier. Gross margin was 87.1% (down from 97.2%) and operating margin -18599.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.54M | $7.02M | $6.88M | $2.36M | $4.65M |
| Growth | -77.99% | +1.99% | +192.02% | -49.32% | -37.30% |
| Net income | $-258.76M | $-157.86M | $-141.43M | $-112.33M | $-70.51M |
| EPS (diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$64.00+133.41%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.96 vs $-1.02
- Surprise
- +5.88%
CLDX news
All CLDX news- Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key EndpointsNasdaq
- Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic DermatitisGlobeNewswire
- Celldex Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaq
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)PR Newswire
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus StudyNasdaqABBV, ABEO, AMRX, ANIP
Celldex Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NEOGNeogen Corporation | 10.55 | -2.77% | $2.30B | vs CLDX |
| NTLAIntellia Therapeutics Inc. | 10.00 | +5.04% | $1.40B | vs CLDX |
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs CLDX |
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs CLDX |
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs CLDX |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs CLDX |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs CLDX |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs CLDX |
Indexes, lists and sector
Celldex Therapeutics stock FAQ
What is Celldex Therapeutics's stock price today?
CLDX last traded at $27.42 as of Nov 20, 4:00 PM EST, down 1.93% on the day. Prices are delayed at least 15 minutes.
Does Celldex Therapeutics pay a dividend?
No. Celldex Therapeutics does not currently pay a regular cash dividend.
Who is Celldex Therapeutics's CEO?
Mr. Anthony S. Marucci M.B.A. is the chief executive officer of Celldex Therapeutics Inc., which has about 198 employees.
Has CLDX ever split its stock?
Yes. The most recent CLDX stock split was a 1-for-15 split on Feb 11, 2019, one of 2 splits on record.
What is the CLDX 52-week high?
The 52-week high for CLDX is $45.14 and the 52-week low is $22.33. The stock is currently 39.3% below its high.